Breaking News, Financial News

Novo Nordisk 3Q

In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%).

Novo Nordisk 3Q09

3Q Revenues:
$2.5 billion (+11%)

3Q Earnings:
$539.7 million (+3%)

YTD Revenues:
$7.4 billion (+16%)

YTD Earnings:
$1.7 million (+21%)

Comments: In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%). NovoSeven sales were up 8%, Norditropin sales were up 14%, and Hormone replacement therapy sales were up 12%. North America sales were up 20%. Sales in Europe were up 2%. International Operations were up 10% and Japan and Oceania sales were up 20%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters